Monte Rosa Therapeutics, Inc.
GLUECIK 0001826457 · last filing Jul 7, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
26,407 bought / 1,026,407 sold
net −1,000,000 sh · −$163.0K
- buys
- 3
- sells
- 5
- insiders active
- 3
Filing tape
Filed Tue, Jul 7, 2026
- −0 sh · $103.0K
Townson Sharon — Chief Scientific Officer
- Exercised6,000Common Stock@ $6.14→ 73,845 held
- Sold5,600Common Stock@ $23.25→ 68,245 held
- Sold400Common Stock@ $24.13→ 67,845 held
- Exercised6,000Stock Option (Right to Buy)→ 197,290 held
Filed Mon, Jul 6, 2026
- −1,000,000 sh
Behbahani Ali — Director
- Disposed of1,000,000Common Stock→ 6,692,298 held
- Acquired15,000Common Stock→ 15,000 held
- Disposed of15,000Common Stock→ 0 held
Filed Wed, Jul 1, 2026
- −0 sh · $60.0K
Janku Filip — Chief Medical Officer
- Exercised5,407Common Stock@ $13.41→ 66,019 held
- Sold5,407Common Stock@ $24.50→ 60,612 held
- Exercised5,407Stock Option (Right to Buy)→ 81,093 held
Insiders on this tape
- Townson SharonChief Scientific Officer
- Behbahani AliDirector
- Janku FilipChief Medical Officer
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.